Pipeline
We are building a pipeline of novel oncolytic immunotherapies that are evolved for optimal clinical performance and aim to deliver on the promise of this innovative therapeutic modality for solid, stroma‑rich cancers.
Our lead candidate THEO‑260 is being evaluated in two Phase 1 trials in patients with platinum‑resistant ovarian cancer: more information about THEO‑260 and these trials can be found below.
THEO-260
Identified using Theolytics’ Adenovo platform, THEO-260 breaks the barriers of the solid tumour microenvironment (TME) using a unique dual targeting mechanism with the potential to transform outcomes for patients with stroma‑rich carcinomas such as ovarian cancer.
THEO‑260 is the first oncolytic immunotherapy evolved for intrinsic targeting and destruction of both patient cancer cells and surrounding stromal cells (cancer‑associated fibroblasts, or CAFs). It further alleviates tumour immunosuppression and triggers anti‑cancer immunity.
A multi‑faceted attack on the patient TME is likely to be required to achieve meaningful clinical impact across a broad range of solid tumours.
THEO‑260 is highly selective for tumour cells and CAFs, with normal cells not impacted. Extensive non‑clinical studies have been conducted that confirm its favourable therapeutic profile, and Phase 1/2 clinical trials in ovarian cancer are ongoing.
THEO-741
THEO-741 was identified using Theolytics’ Adenovo platform specifically to overcome the challenges faced in the treatment of colorectal cancer.
Clinical Studies
THEO‑260 is being investigated in two trials in advanced ovarian cancer, the first being the ongoing Phase 1/2a trial, OCTOPOD‑IV in the UK, Spain and Canada (NCT06618235) and a second US trial, OCTOPOD‑IP, at the The University of Texas MD Anderson Cancer Center (NCT07211659).
Intravenous Delivery
OCTOPOD-IV
🇬🇧 🇪🇸 🇨🇦
A first‑in‑human, multi‑centre trial to assess the safety, tolerability, and preliminary efficacy of THEO‑260 in patients with high‑grade serous ovarian or endometrioid cancer delivered intravenously.
Recruitment is open in the UK, Spain and Canada.
Details of the OCTOPOD‑IV trial can be found at clinicaltrials.gov under study identifier NCT06618235.
Intraperitoneal Delivery
OCTOPOD-IP
🇺🇸
A first‑in‑human trial to assess the safety, tolerability, and preliminary efficacy of THEO‑260 in patients with high‑grade serous ovarian or endometrioid cancer administered by direct intraperitoneal delivery.
Recruitment is open in the US at the MD Anderson Cancer Center.
Details of the OCTOPOD‑IP trial can be found at clinicaltrials.gov under study identifier NCT07211659.